In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

Auspex Pharmaceuticals raises $15mm in debt financing

30 Mar 2015

Executive Summary

Concurrent with a $19.5mm Series E round, Oxford Finance provided orphan drug developer Auspex Pharmaceuticals Inc. (focused on hyperkinetic movement disorders) with a four-year $15mm term loan facility; $5mm will go towards debt repayment, and the remainder will finance operations. Just last month Auspex filed for an initial public offering. Should Auspex net at least $40mm in its IPO, Oxford will extend the interest-only repayment period of this loan from 12 to 18 months.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • Molecular Diversity
        • Natural Products
Deal Status
  • Final
Deal Type
  • Financing
    • Nonconvertible Debt
    • Private Placement

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By